GeneDx Holdings (NASDAQ: WGS) reported Q1 EPS of ($0.28), $0.27 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $102.3 million versus the consensus estimate of $112.45 million.

GUIDANCE:

GeneDx Holdings sees Q2 2026 revenue of $110-112 million, versus the consensus of $130.3 million.

GeneDx Holdings sees FY2026 revenue of $475-490 million, versus the consensus of $550 million.

For earnings history and earnings-related data on GeneDx Holdings (WGS) click here.